Gain Therapeutics shares surge 25.78% after hours as analysts raise price targets and maintain Buy ratings.

Gain Therapeutics surged 25.78% in after-hours trading following analyst upgrades. Roth Capital raised its price target for GANX to $10 from $6 while maintaining a "Buy" rating, and HC Wainwright & Co. reiterated its $8.00 price target with a "Buy" recommendation. Both moves reinforced positive sentiment amid consistent analyst support for the biotechnology firm’s pipeline, including its GBA1 Parkinson’s candidate GT-02287. The upgrades, combined with a broader analyst consensus of 202.9% upside potential, likely drove the sharp after-hours rally.